30 closest matches · ranked by relevance
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
SARS-CoV-2 · COVID-19
Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
COVID-19
Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…
Corona Virus Infection · Pregnancy Related · Neonatal Infection
Primary: Antibody Concentrations in Maternal Blood in Pregnant Women in England — 37.2; 7.2; 80.3; 590.5 CAU/ml
SARS-CoV-2 Infection
Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
Covid19
Primary: Participants Enrolled — 36 Participants
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
Confirmed Coronavirus Disease
Primary: Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7 — 6; 0; 20; 8 Participants — p=0.0346
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
COVID-19
Primary: Improvement in Oxygenation — 25.7; 29.7 ratio
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants
Covid19
Primary: Comparison of Participant Clinical Status Between Treatment Arms — 28; 40; 112; 129 participants — p=0.008
Sars-CoV2 · Acute Respiratory Distress Syndrome · COVID-19
Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant
Covid19
Primary: Body Temperature — 98.1 degrees Fahrenheit
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…
COVID-19 Testing
Primary: Reinfection With SARS-CoV-2 — 12; 77; 68; 957 Participants
Corona Virus Infection
Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points — 10.0; 10.0; 12.0 days — p=0.9561
COVID
Primary: Number of Participants With Intubation or Death — 5; 1 Participants
COVID-19
Primary: Hierarchical Composite Endpoint — 81; 73 score on a scale (range 1 to 152)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
SARS-CoV-2 · Covid19 · Corona Virus Infection
Primary: Rate of Perinatal Transmission of SARS-CoV-2 — 12.3 percentage of participants
COVID
Primary: Number of Participants With SARS-CoV-2 IgG Antibodies — 14 Participants
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
COVID-19 · Influenza
Primary: Positive Percent Agreement — 52 percent of nasal swabs
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale